---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-25-000037"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2025-06-13T23:59:59+00:00"
generated_at: "2026-05-19T09:28:21.110233+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Lisata Therapeutics raises CEO salary to $717,229, CMO salary to $599,342 in amended employment agreements

## Summary
- CEO David Mazzo base salary increased to $717,229 from $633,032; $12,000 non-accountable expense allowance removed.
- CMO Kristen Buck base salary increased to $599,342 from $550,000.
- Amended severance terms for CEO, CMO, CAO Nisco, and GC Imam; includes COBRA reimbursement changes and Section 409A clarifications.
- Change in Control definition amended to include shareholder-approved complete liquidation, subject to 409A requirements.

## SEC filing metadata
- accession: 0000320017-25-000037
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2025-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001725000037/0000320017-25-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001725000037/clbs-20250610.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-25-000037
- JSON: https://secwatch.observer/filing/0000320017-25-000037.json
- Plain text: https://secwatch.observer/filing/0000320017-25-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.